CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.

ABSTRACT:

Objectives

To test whether CSF Alzheimer disease biomarkers (β-amyloid 42 [Aβ42], tau, phosphorylated tau at threonine 181 [ptau181], tau/Aβ42, and ptau181/Aβ42) predict future decline in noncognitive outcomes among individuals cognitively normal at baseline.

Methods

Longitudinal data from participants (N = 430) who donated CSF within 1 year of a clinical assessment indicating normal cognition and were aged 50 years or older were analyzed. Mixed linear models were used to test whether baseline biomarker values predicted future decline in function (instrumental activities of daily living), weight, behavior, and mood. Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination scores were also examined.

Results

Abnormal levels of each biomarker were related

SUBMITTER: Roe CM 

PROVIDER: S-EPMC3854826 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature